Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 11Other hematologic neoplasm 3Plasma cell 2Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Head and Neck Neoplasms 2Thyroid Neoplasms 1Thyroid Diseases 1Prostatic Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Lymphoma 1Lung Neoplasms 1Hereditary Sensory and Autonomic Neuropathies 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 9Nivolumab 5epacadostat 2Thiotepa 2Nonlinear Optical Microscopy 2Magnetic Resonance Spectroscopy 2Magnetic Resonance Imaging 2Ipilimumab 2Filgrastim 2Cytological Techniques 2Cyclophosphamide 2Biopsy, Fine-Needle 2Biopsy 2vocimagene amiretrorepvec 1ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1spartalizumab 1sapanisertib 1romidepsin 1relatlimab 1poly ICLC 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1motexafin gadolinium 1larotrectinib 1ipatasertib 1fludarabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × Panobinostat × Head & Neck × Clear all
NCT01341834 2018-04-24

Safety and Tolerability Study of RAD001 and LBH589 in All Solid Tumors With Enrichment for EBV Driven Tumors

National Cancer Centre, Singapore

Phase 1 Unknown
49 enrolled
Head & NeckLymphoid

Nasopharyngeal Carcinoma, Lymphoma, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡